idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
WifOR Institute's recent analysis, published in The Lancet Oncology, calculates that increasing access to [¹⁷⁷Lu]PSMA therapy for eligible patients could generate $725 million in economic potential. This impact is projected across nine selected countries between 2023 and 2029.
[¹⁷⁷Lu]PSMA is a theranostic treatment that combines both therapeutics and diagnostics to target prostate-specific membrane antigens (PSMA) found in cancer cells. Compared to standard treatments, patients receiving [¹⁷⁷Lu]PSMA therapy experience fewer side effects and have higher chances of recovery.
These enhanced health outcomes translate into substantial economic benefits. By reducing time lost to illness, individuals can return to work, participate in society, and maintain productivity for longer periods. This sustained workforce activity boosts both economic performance and societal well-being, transforming health improvements into tangible gains for individuals and society alike. Beyond these direct effects, increased productivity creates two types of ripple effects:
1. Indirect effects: Companies with healthier employees are able to increase spending on goods and services, thereby enhancing business-to-business activities.
2. Induced effects: Higher employee spending supports other sectors, stimulating overall economic growth.
Moreover, the study considered the value of unpaid work such as caregiving and volunteering that healthier individuals can contribute to society. These efforts, often overlooked in national accounting systems, further underscore the wider social impact of improved health outcomes.
“Our analysis shows the economic potential of using advanced cancer treatments like [¹⁷⁷Lu]PSMA to their full extent,” says Dr. Malina Müller, Head of Health Economics at WifOR Institute. “Access to advanced cancer treatment delivers returns not only in individual and public health outcomes but also in measurable economic benefits and societal well-being.”
The analysis is part of The Lancet Oncology Commission report “Radiotherapy and theranostics: a Lancet Oncology Commission.”
About the Social Impact Approach:
The Social Impact approach measures the societal benefits of new medical treatments. The first step compares the health improvements from a new therapy to the current standard treatment, measured in quality-adjusted life years (QALYs). These health benefits are then converted into economic terms by calculating the value of increased productivity – both for paid and unpaid work. The last step monetizes these benefits to show the overall economic impact of the therapy.
Method:
WifOR Institute compared full treatment for all eligible patients with the current rate in nine countries representative of high-, upper-middle-, and lower-middle-income economies: Australia, Germany, India, Jordan, the Netherlands, the Philippines, South Africa, Thailand, and the United States. To determine eligibility for [¹⁷⁷Lu]PSMA therapy, WifOR analyzed prostate cancer incidence using data from the 2022 GLOBOCAN database, focusing on advanced-stage cases where the therapy is most applicable. Approximately 90% of patients with metastatic castration-resistant prostate cancer are considered suitable for this treatment based on criteria from the VISION trial.
About WifOR Institute
WifOR is an independent economic research institute, founded in 2009 as a spin-off from the Technical University of Darmstadt, Germany. As experts in macroeconomic analysis, WifOR's research focuses on labor markets, health, and sustainability. Through its studies, the institute aims to enable data-based solutions to labor market challenges, set global standards in impact measurement, and highlight the value of health investments worldwide. WifOR has over 75 employees in Germany, Greece, Latin America, and the USA.
Dr. Malina Müller
Head of Health Economics
E-mail: malina.mueller@wifor.com
Abdel-Wahab, M., Giammarile, F., Carrara, M., Paez, D., Hricak, H., Ayati, N., Li, J. J., Mueller, M., Aggarwal, A., Al-Ibraheem, A., Alkhatib, S., Atun, R., Bello, A., Berger, D., Delgado Bolton, R. C., Buatti, J. M., Burt, G., Ciraj Bjelac, O., Cordero-Mendez, L., Dosanjh, M., Eichler, T., Fidarova, E., Gondhowiardjo, S., Gospodarowicz, M., Grover, S., Hande, V., Harsdorf-Enderndorf, E., Herrmann, K., Hofman, M. S., Holmberg, O., Jaffray, D., Knoll, P., Kunikowska, J., Lewis, J. S., Lievens, Y., Mikhail-Lette, M., Ostwald, D., Palta, J. R., Peristeris, P., Rosa, A. A., Salem, S. A., dos Santos, M. A., Sathekge, M. M., Shrivastava, S. K., Titovich, E., Urbain, J.-L., Vanderpuye, V., Wahl, R. L., Yu, J. S., Zaghloul, M. S., Zhu, H. C., Scott, A. M. Radiotherapy and theranostics: a Lancet Oncology Commission. The Lancet Oncology 2024; published online September 30th. https://doi.org/10.1016/S1470-2045(24)00407-8.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00407-8/fullt...
Ratio of cost of treatment to GDP per capita
The Lancet Oncology Commission
Dr. Malina Müller, Head of Health Economics
WifOR Institute
Criteria of this press release:
Journalists
Economics / business administration, Medicine
transregional, national
Research results, Scientific Publications
English
Ratio of cost of treatment to GDP per capita
The Lancet Oncology Commission
Dr. Malina Müller, Head of Health Economics
WifOR Institute
You can combine search terms with and, or and/or not, e.g. Philo not logy.
You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).
Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.
You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).
If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).
